Methylation of human papillomavirus-52 and -58 is a candidate biomarker in cervical neoplasia

Journal of Clinical Virology

Volumn 58, Issue 1, 2013, Pages 149-154

  Murakami, Isao ^a   Fujii, Takuma ^a,b   Dan, Katsuaki ^a   Saito, Miyuki ^a   Ohno, Akiko ^a   Iwata, Takashi ^a   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Cervical neoplasia; DNA methylation; Human papillomavirus 52; Human papillomavirus 58

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; CPG ISLAND; DISEASE MARKER; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; L1 GENE; MAJOR CLINICAL STUDY; METHYLATION; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU; VIRUS GENE;

EID: 84881551339     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.06.026     Document Type: Article

References (30)

1. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
2. Masumoto N., Fujii T., Ishikawa M., Mukai M., Saito M., Iwata T., et al. Papanicolaou tests and molecular analyses using new fluid-based specimen collection technology in 3000 Japanese women. Br J Cancer 2003, 88:1883-1888.
3. Onuki M., Matsumoto K., Satoh T., Oki A., Okada S., Minaguchi T., et al. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 2009, 100:1312-1316.
4. Stünkel W., Bernard H.U. The chromatin structure of the long control region of human papillomavirus type 16 represses viral oncoprotein expression. J Virol 1999, 73:1918-1930.
5. Zhao W., Noya F., Chen W.Y., Townes T.M., Chow L.T., Broker T. Trichostatin a up-regulates human papillomavirus type 11 upstream regulatory region-E6 promoter activity in undifferentiated primary human keratinocytes. J Virol 1999, 73:5026-5033.
6. Hoelzer K., Shackelton L.A., Parrish C.R. Presence and role of cytosine methylation in DNA viruses of animals. Nucleic Acids Res 2008, 36:2852-2937.
7. Kalantari M., Calleja-Macias I.E., Tewari D., Hagmar B., Lie K., Barrera-Saldana H.A., et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 2004, 78:12762-12772.
8. Turan T., Kalantari M., Calleja-Macias I.E., Cubie H.A., Cuscieri K., Villa L.L., et al. Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression?. Virology 2006, 349:175-183.
9. Turan T., Kalantari M., Cuscieri K., Cubie H.A., Skomedal H., Bernard H.U. High-throughput detection of human papillomavirus-18 L1 gene methylation, a candidate biomarker for the progression of cervical neoplasia. Virology 2007, 361:185-193.
10. Ding D.C., Chiang M.H., Lai H.C., Hsiung C.A., Hsieh C.Y., Chu T.Y. Methylation of the long control region of HPV16 is related to the severity of cervical neoplasia. Eur J Obstet Gynecol Reprod Biol 2009, 147:215-220.
11. Brandsma J.L., Sun Y., Lizardi P.M., Tuck D.P., Zelterman D., Haines G.K., et al. Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology 2009, 389:100-107.
12. Sun C., Reimers L., Burk R.D. Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer. Gynecol Oncol 2011, 121:59-63.
13. Piyathilake C.J., Macaluso M., Alvarez R.D., Chen M., Badiga S., Edberg J.C., et al. A higher degree of methylation of the HPV 16 E6 gene is associated with a lower likelihood of being diagnosed with cervical intraepithelial neoplasia. Cancer 2011, 117:957-963.
14. Hong D., Ye F., Lu W., Hu Y., Wan X., Chen Y., et al. Methylation status of the long control region of HPV 16 in clinical cervical specimens. Mol Med Rep 2008, 1:555-560.
15. Kalantari M., Villa L.L., Calleja-Macias I.E., Bernard H.U. Human papillomavirus-16 and -18 in penile carcinomas: DNA methylation, chromosomal recombination and genomic variation. Int J Cancer 2008, 123:1832-1840.
16. Kalantari M., Lee D., Calleja-Macias I.E., Lambert P.F., Bernard H.U. Effects of cellular differentiation, chromosomal integration and 5-aza-2'-deoxycytidine treatment on human papillomavirus-16 DNA methylation in cultured cell lines. Virology 2008, 374:292-303.
17. Kalantari M., Chase D.M., Tewari K.S., Bernard H.U. Recombination of human papillomavirus-16 and host DNA in exfoliated cervical cells: a pilot study of L1 gene methylation and chromosomal integration as biomarkers of carcinogenic progression. J Med Virol 2010, 82:311-320.
18. Badal V., Chuang L.S.H., Tan E.H.H., Badal S., Villa L.L., Wheeler C.M., et al. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol 2003, 77:6227-6234.
19. Kalantari M., Garcia-Carranca A., Morales-Vazquez C.D., Zuna R., Montiel D.P., Calleja-Macias I.E., et al. Laser capture microdissection of cervical human papillomavirus infection: copy number of the virus in cancerous and normal tissue and heterogeneous DNA methylation. Virology 2009, 380:261-267.
20. Fernandez A.F., Rosales C., Lopez-Nieva P., Grana O., Ballestar E., Ropero S., et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 2009, 19:438-451.
21. Bhattacharjee B., Sengupta S. CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology 2003, 77:6227-6234.
22. Badal S., Badal V., Calleja-Macias I.E., Kalantari M., Chuang L.S.H., Li B.F.L., et al. The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology 2004, 324:483-492.
23. Satoh T., Matsumoto K., Fujii T., Sato O., Gemma N., Onuki M., et al. Rapid genotyping of carcinogenic human papillomavirus by loop-mediated isothermal amplification using a new automated DNA test (Clinichip HPV). J Virol Methods 2013, 188:83-93.
24. Pretorius R.G., Zhang W.H., Belinson J.K., Huang M.N., Wu L.Y., Zhang X., et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004, 191:430-434.
25. Gage J.C., Hanson V.W., Abbey K., Dippery S., Gardner S., Kubota J., et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006, 108:264-272.
26. Matsumoto K., Oki A., Furuta R., Maeda H., Yasugi T., Takatsuka N., et al. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer 2011, 128:2898-2910.
27. Hariri J., Oster A. The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol 2007, 26:223-228.
28. Negari G., Vittadello F., Romano F., Kasal A., Rivasi F., Girlando S., et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 2004, 445:616-620.
29. del Pino M., Garcia S., Fusté V., Alonso I., Fusté P., Torné A., et al. Value of p16INK4a as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. Am J Obstet Gynecol 2009, 201:488e1-488e7.
30. Ozaki S., Zen Y., Inoue M. Biomarker expression in cervical intraepithelial neoplasia: potential progression predictive factors for low-grade lesions. Hum Pathol 2011, 42:1007-1012.